{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024182","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.264903+00:00","generated_at":"2026-06-21T23:33:05.544342+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MindMed Q3 net loss $16.5M, cash $154.5M; Phase 2b GAD trial on track for H2 2023 readout","bullets":["Net loss of $16.5M for Q3 2022 vs $17.2M in Q3 2021; nine-month net loss $51.9M vs $76.2M.","Cash and equivalents $154.5M as of Sept 30, 2022; expected to fund operations into first half of 2025.","Raised ~$60M in gross proceeds via at-the-market program and public offering during Q3.","Phase 2b dose-optimization trial of MM-120 (LSD) in GAD initiated; topline data expected H2 2023.","Advanced IND-enabling studies for MM-402 (R-MDMA) for autism; Phase 1 planned for 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024182","json":"https://secwatch.observer/filing/0000950170-22-024182.json","markdown":"https://secwatch.observer/filing/0000950170-22-024182.md","text":"https://secwatch.observer/filing/0000950170-22-024182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017022024182/0000950170-22-024182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017022024182/mnmd-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:33:05.544342+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac5e796293330366b3594fe0117cd24bdf96c9a0","claim":"Definium Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $16.5 million.","evidence_excerpt":"The net loss for the three months ended September 30, 2022 was $16.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017022024182/0000950170-22-024182-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$16.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}